Personalized mRNA Melanoma Vaccine Cuts Recurrence Risk by 42% in Phase 3 Trial
A personalized mRNA vaccine developed by Moderna and Merck, when combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. The results come from the Phase 3 INTerpath-001 trial, which enrolled 1,137 patients with high-risk melanoma, and were presented at the European Society for Medical Oncology … Read more